See the DrugPatentWatch profile for Wegovy
When does Wegovy's US patent expire?
The primary patent protecting Wegovy (semaglutide) in the United States is set to expire in 2031 [1]. This patent covers the composition of matter for semaglutide [1].
What other patent protections does Wegovy have?
Beyond the composition of matter patent, Wegovy has additional patents that may extend its market exclusivity. These include patents related to its formulation and methods of use [1]. DrugPatentWatch.com tracks these patents and their expiration dates [1].
How does Wegovy's patent situation compare to Ozempic?
Wegovy and Ozempic are both brand names for semaglutide, but they are indicated for different uses. Wegovy is approved for chronic weight management, while Ozempic is indicated for type 2 diabetes. While they share the same active ingredient, their patent landscapes can have nuances regarding specific formulations and uses, though the core semaglutide patent in the US is also set to expire around 2031 for Ozempic [1].
Can generic versions of Wegovy be released before patent expiration?
Generic manufacturers often challenge existing patents, seeking to invalidate them or find loopholes to launch their products earlier. If a patent is successfully challenged or if a court rules in favor of a generic company, it could lead to an earlier market entry for generic semaglutide [2]. DrugPatentWatch.com monitors such legal challenges and their potential impact on patent exclusivity [1].
What is the typical timeline for generic drug approval after patent expiration?
Following the expiration of primary patents, regulatory bodies like the FDA review applications for generic drug approvals. The timeline for approval can vary depending on the complexity of the drug and the completeness of the generic manufacturer's submission. Once approved, generic versions typically enter the market, often leading to significant price reductions [3].
Who are Wegovy's main competitors in the weight loss market?
Wegovy competes with other weight management medications, including other GLP-1 receptor agonists like tirzepatide (marketed as Zepbound for weight loss and Mounjaro for diabetes) and liraglutide (Saxenda) [4]. The competitive landscape is evolving with new drug development and potential market entries of generics.
What is the mechanism of action for Wegovy?
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of the natural GLP-1 hormone, which helps regulate appetite and food intake by acting on receptors in the brain and slowing gastric emptying [5]. This leads to reduced calorie consumption and subsequent weight loss.